丹参酮联合前列地尔治疗缺血性肠病患者的疗效及对血清肠脂肪酸结合蛋白与D-二聚体的影响  

Therapeutic Effect of Tanshinone Combined with Alprostadil on Patients with Ischemic Bowel Disease and Its Effect on Serum Intestinal Fatty Acid Binding Protein and D Dimer

作　　者：贾国青 李春涛 JIA Guo-Qing;LI Chun-Tao(Department of Gastroenterology,Beijing Shunyi District Hospital affiliated to Capital Medical University,Beijing 101300,China)

机构地区：[1]首都医科大学附属北京顺义区医院消化科,北京101300

出　　处：《中国药物经济学》2023年第4期62-64,68,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨丹参酮联合前列地尔治疗缺血性肠病患者的疗效及对血清肠脂肪酸结合蛋白(I-FABP)、D-二聚体的影响。方法选取2020年1月至2023年1月首都医科大学附属北京顺义区医院收治的150例缺血性肠病患者作为研究对象,按随机数字表法分为观察组与对照组,各75例。对照组在基础治疗同时应用前列地尔进行治疗,观察组在对照组基础上联合丹参酮治疗。比较两组治疗有效率、肠相关功能恢复时间、用药不良反应以及治疗前后血清I-FABP、D-二聚体。结果观察组治疗有效率为92.00%,高于对照组的80.00%,差异有统计学意义(χ^(2)=4.485,P=0.034);观察组肠供血时间、肠功能恢复时间、腹痛缓解时间、肠镜恢复时间以及便血消失时间均短于对照组,差异有统计学意义(P<0.05);治疗前,两组D-二聚体、I-FABP水平比较差异无统计学意义(P>0.05);治疗后,两组D-二聚体、I-FABP水平均下降,且观察组均低于对照组,差异有统计学意义(P<0.05);两组患者治疗期间均未出现较为严重的不良反应。结论对缺血性肠病患者采用丹参酮联合前列地尔治疗能取得更优异的治疗效果,且可促进患者肠功能早日恢复。Objective To explore the therapeutic effect of tanshinone combined with alprostadil on patients with ischemic bowel disease and the effects on serum intestinal fatty acid binding protein and D-dimer.Methods A total of 150 patients with ischemic bowel disease admitted to Beijing Shunyi District Hospital affiliated to Capital Medical University from January 2020 to January 2023 were selected as the study subjects.They were randomly divided into an observation group and a control group,with 75patients in each group.The control group was treated with alprostadil on the basis of basic treatment,while the observation group was treated with tanshinone on the basis of the control group.Treatment response rate,recovery time of enteric-related function,adverse drug reactions,serum intestinal fatty acid binding protein and D-dimer before and after treatment were compared between the two groups.Results The effective rate of the observation group was 92.00%,higher than 80.00%in the control group,the difference was statistically significant(χ^(2)=4.485,P=0.034).The intestinal blood supply time,intestinal function recovery time,abdominal pain relief time,colonoscopy recovery time and stool blood disappearance time in the observation group were shorter than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there was no statistical significance in D-dimer and I-FABP levels between the two groups(P<0.05).After treatment,D-dimer and I-FABP levels were decreased in the two groups,and the observation group was lower than the control group,with statistical significance(P<0.05).No serious adverse reactions occurred in the two groups during the treatment.Conclusion Tanshinone combined with alprostadil can achieve better therapeutic effect and promote early recovery of intestinal function in patients with ischemic bowel disease.

关 键 词：丹参酮 前列地尔 缺血性肠病 肠脂肪酸结合蛋白 D-二聚体 

分 类 号：R574.5[医药卫生—消化系统] R574.6[医药卫生—内科学] R975[医药卫生—临床医学]